Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient

Virology Journal

Mohamed I Radwan¹  Mohamed H Emara¹ 

[1] Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt

关键词: lamivudine;    pegylated interferon;    hepatitis C;    occult hepatitis B;   

Others  :  1155614
DOI  :  10.1186/1743-422X-8-518

 received in 2011-09-15, accepted in 2011-11-14,  发布年份 2011

【 摘 要 】

We reported a 23 years old male with chronic hepatitis C virus infection, discontinued from pegylated interferon/ribavirin combination therapy due to a lack of early virological response. He has developed activation of occult hepatitis B virus that was successfully treated by a one year of lamivudine therapy.

【 授权许可】

   
2011 Emara and Radwan; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P: Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001, 34:194-203.
• [2]Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk G, Thomas D, Torbenson M: Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clinical Virol 2007, 39:101-105.
• [3]Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M, Raimondo G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341:22-6.
• [4]Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, Akagi S, Watanabe M, Kinoshita Y: Co-infection by serologically silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001, 63:220-227.
• [5]Nirei K, Kaneko M, Moriyama M, Arakawa Y: The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000, 43:95-101.
• [6]Sheu J, Huang G, Shih L: Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992, 103:1322-1327.
• [7]Emara MH, El-Gammal NE, Mohamed LA, Bahgat MM: Occult Hepatitis B Infection in Egyptian Chronic Hepatitis C Patients: Prevalence, Impact on Pegylated Interferon/Ribavirin Therapy. Virol J 2010, 7:324. BioMed Central Full Text
• [8]Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V: Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents 2003, 17:172-5.
• [9]Michalak T, Pardoe I, Coffin C, Churchill N, Freake D, Smith P: Occult lifelong persistence of infectious hepadna virus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999, 29:928-38.
• [10]Weber B: Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 2006, 78:S59-S65.
• [11]Shih C, Lo S, Miyamura T, Chen S, Lee Y: Suppression of Hepatitis B Virus Expression and Replication by Hepatitis C Virus Core Protein in HuH-7 Cells. J Virol 1993, 67:5823-5832.
• [12]European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
• [13]Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepato 2008, 49:625-657.